Literature DB >> 21421804

Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.

Deepak Raina1, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I Shapiro, Jeffrey Supko, Surender Kharbanda, Donald Kufe.   

Abstract

Non-small cell lung cancer (NSCLC) cells are often associated with constitutive activation of the phosphoinositide 3-kinase (PI3K) → AktmTOR pathway. The mucin 1 (MUC1) heterodimeric glycoprotein is aberrantly overexpressed in NSCLC cells and induces gene signatures that are associated with poor survival of NSCLC patients. The present results show that the MUC1 C-terminal subunit (MUC1-C) cytoplasmic domain associates with PI3K p85 in NSCLC cells. We show that inhibition of MUC1-C with cell-penetrating peptides blocks this interaction with PI3K p85 and suppresses constitutive phosphorylation of Akt and its downstream effector, mTOR. In concert with these results, treatment of NSCLC cells with the MUC1-C peptide inhibitor GO-203 was associated with downregulation of PI3K → Akt signaling and inhibition of growth. GO-203 treatment was also associated with increases in reactive oxygen species (ROS) and induction of necrosis by a ROS-dependent mechanism. Moreover, GO-203 treatment of H1975 (EGFR L858R/T790M) and A549 (K-Ras G12S) xenografts growing in nude mice resulted in tumor regressions. These findings indicate that NSCLC cells are dependent on MUC1-C both for activation of the PI3K → Akt pathway and for survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421804      PMCID: PMC3092019          DOI: 10.1158/1535-7163.MCT-10-1050

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

1.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin.

Authors:  Y Li; H Kuwahara; J Ren; G Wen; D Kufe
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

4.  The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.

Authors:  Y Li; J Ren; W Yu; Q Li; H Kuwahara; L Yin; K L Carraway; D Kufe
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

5.  MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.

Authors:  Rehan Ahmad; Deepak Raina; Vishal Trivedi; Jian Ren; Hasan Rajabi; Surender Kharbanda; Donald Kufe
Journal:  Nat Cell Biol       Date:  2007-11-25       Impact factor: 28.824

6.  Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Authors:  Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn R Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

7.  The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

Authors:  Selvi Ramasamy; Sekhar Duraisamy; Sergei Barbashov; Takeshi Kawano; Surender Kharbanda; Donald Kufe
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

Review 8.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Jeffrey A Engelman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

Authors:  Takeshi Shimamura; Danan Li; Hongbin Ji; Henry J Haringsma; Elizabeth Liniker; Christa L Borgman; April M Lowell; Yuko Minami; Kate McNamara; Samanthi A Perera; Sara Zaghlul; Roman K Thomas; Heidi Greulich; Susumu Kobayashi; Lucian R Chirieac; Robert F Padera; Shigeto Kubo; Masaya Takahashi; Daniel G Tenen; Matthew Meyerson; Kwok-Kin Wong; Geoffrey I Shapiro
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  91 in total

1.  MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Donald Kufe
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

Review 2.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain.

Authors:  Govind Panchamoorthy; Hala Rehan; Akriti Kharbanda; Rehan Ahmad; Donald Kufe
Journal:  Hybridoma (Larchmt)       Date:  2011-12

4.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

Review 5.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 6.  Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?

Authors:  Andrea Riccardo Filippi; Jacopo Di Muzio; Serena Badellino; Cristina Mantovani; Umberto Ricardi
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

8.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

9.  MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Akriti Kharbanda; Donald Kufe
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

10.  Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Authors:  Akriti Kharbanda; Hasan Rajabi; Caining Jin; Deepak Raina; Donald Kufe
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.